Effects of Dietary Supplementation of Bovine Lactoferricin on Rumen Microbiota, Lactation, and Health in Dairy Goats

Yuexin Shao \(^1\), Xian Zhang \(^1\), Huawen Zhang \(^1\), Bowen Tian \(^1\), Yunan Weng \(^1\), Jiangtao Huang \(^1\), Christopher D. Lu\(^{2*}\) and Huaiping Shi\(^{1*}\)

\(^1\) Shaanxi Key Laboratory of Molecular Biology for Agriculture, College of Animal Science and Technology, Northwest A&F University, Yangling, China, \(^2\) College of Agriculture, Forestry and Natural Resource Management, University of Hawaii, Hilo, HI, United States

This study aimed to investigate the biological effects of supplementation of bovine lactoferricin (BLFc) at the rate of 100 mg/kg/day (LF-1) or 200 mg/kg/day (LF-2) in lactating dairy goats. Dietary BLFc supplementation increased the concentration of lactoferrin (LF) in the milk and serum \((p < 0.05)\) without affecting the feed intake. In the LF-1 group, serum Fe, total antioxidant (T-AOC), and immunoglobulin A (IgA) were increased \((p < 0.05)\), while malondialdehyde (MDA) was decreased \((p < 0.05)\). In the LF-2 group, ruminal fluid pH value was decreased \((p < 0.05)\), and the composition of ruminal microbiota on day 42 was more diversified. Firmicutes phylum in the LF-2 group was the most abundant phyla. In contrast, Bacteroidetes phylum in the control group and the LF-1 group were the most abundant. Lower milk somatic cell count and higher IgA were observed in the LF-1 group and the LF-2 group than those in the control group \((p < 0.05)\). These results suggested beneficial effects of supplementation of 100 mg/kg/day BLFc on reducing the oxidative stress and altering diversity of ruminal microbiota.

Keywords: lactoferricin, lactation, ruminal microorganisms, immunoglobulin A, goat

INTRODUCTION

Lactoferrin (LF) is highly expressed in the Colostrum. Lactoferricin of ruminant is a peptide containing five tryptophan, three lysine, and several aromatic amino acid residues released from the N-terminal by pepsin hydrolysis under acidic conditions, with a molecular weight of approximately 3.1 KU \((1)\). It is notable that bovine lactoferricin (BLFc) as an animal-derived antimicrobial peptide could induce beneficial health effects, that is, absorption of iron, antibacterial, anti-cancer, and immune ability, and cell proliferation \((2–4)\). Moreover, a recent study in piglets indicated that LFc could increase the antioxidant capacity and decrease diarrhea rate, suggesting the possible correlation between consumption of LFc and composition of gut microbiota \((5–7)\). Rumen is a vital organ of nutrient digestion and metabolism and absorption in goats, and its microbial diversity will affect the health status of animals \((8, 9)\). It was reported that the different compositions of ruminal microbiota were linked to the different levels of somatic cell count (SCC) and mastitis in ruminants \((10, 11)\).
Recessive or subclinical mastitis is common in lactating dairy goats. The clinical manifestations include redness and swelling of the breast and elevated body temperature, and a sharp increase in the number of SCC. Goat milk fails to meet the national sales standards that possibly results in economic losses. When farmers use antibiotics without discretion, these antibiotics may easily lead to drug resistance and residue in milk. There, therefore, is a need for feed additives with no drug resistance, low residue, and low toxicity in combating recessive mastitis. Feed additives, such as micro preparations, probiotics, acid preparations, and antimicrobial peptides, decreased the risk of various diseases (12, 13). The BLFc used in this study belongs to antimicrobial peptides of animal origin. However, little information is available about how BLFc affects dairy goat health and reduces the rate of subclinical mastitis. We speculate that after the ingested BLFc reaching the rumen may interact with ruminal microbiota. The diverse and complex communities of microorganisms play important roles in animal health. We incorporated two different doses of BLFc into the diets of Xinong Saanen dairy goats to investigate the effects of BLFc on lactation performance, antioxidant ability, immune response, and rumen microbial composition.

MATERIALS AND METHODS

The experiment was carried out with the approval of the Animal Use and Care Committee of Northwest A&F University in China (No.IASCAAS-PG-39).

Materials

Bovine lactoferricin was produced and supplied by DeYi Biotechnology., LTD (Hunan, China). The main component of BLFc is the product of chimeric expression of lactoferricin (BLF17-30) and lactoferrampin (LFAMPIN 265-284), two active regions of LF with a total of 31 amino acid residues by genetic engineering technology. The amino acid sequence is consistent with the natural sequence, and its molecular weight is 3,953 Da.

Animals, Experimental Design, and Diets

Twenty-one Xinong Saanen goats [60 ± 10 days in milk (DIM)] were used, and three BLFc treatments used were (a) control, fed the basal diet without BLFc supplementation; (b) orally supplemented with 100 mg/kg/day of BLFc (low dose, LF-1); and (c) orally supplemented with 200 mg/kg/day of BLFc (high dose, LF-2). BLFc supplements were thoroughly mixed with the concentrated feed and were fed first to goats to ensure complete consumption. After 2 weeks of adjustment phase, the experimental phased consisted of 42 days. All goats were housed indoors at Saanen Dairy Goat Farm of Northwest A&F University in China (Yangling, China; 34°16′56.24″N, +108°4′27.95″E). The temperature in the house was approximately 25 °C. The goats were fed basal diet, such as corn silage, a concentrate mixture, and alfalfa hay at 8:00 a.m. and 4:00 p.m. daily. The component of ration is recorded seen in Supplementary Table 1. The feed intake of the goats was recorded daily during the 6-week experimental phase.

Milk and Serum Analysis

Prior to oral supplementation of BLFc, jugular blood samples (5 ml) were collected (seven goats per treatment) on days 0, 14, 28, and 42. Blood samples were centrifuged at 3,500 rpm for 5 min and serum samples were stored at −80 °C. Seven goats per group were milked two times daily at 06:30 a.m. and 03:00 p.m., and AM and PM samples were taken and composited as daily samples. The composited milk samples were analyzed for milk fat, protein, lactose, and SCC (cells/ml) using a Combi 300 counter (Bentley, PA, USA). Additionally, LF and immunoglobulin A (IgA) in milk and serum were determined using ELISA kits (Jiangsu Meibiao Biotechnology Co. LTD, Nanjing, China). Serum Fe was analyzed by chromatometry (A039-1-1; Nanjing Jiancheng Bioengineering Institute, Nanjing, China). The malondialdehyde (MDA) of serum was measured using the thiobarbituric acid (TBA) method (A003-1-2; Nanjing Jiancheng Bioengineering Institute, Nanjing, China). Total antioxidant content (T-AOC) of serum was measured using a Total Antioxidant Capacity Assay Kit (A015-1; Nanjing Jiancheng Bioengineering Institute, Nanjing, China) based on the ferric reducing antioxidant power. The samples were detected at 520 nm, and the T-AOC was calculated according to the standard curve.

Analysis of Rumen Microbial Diversity

At the end of the experimental phase, fresh rumen fluid samples were collected randomly via a stomach tube from three dairy goats of each group. Before sampling, the mouth of a goat was opened and then, the head of a sampler connected with a vacuum pump was inserted into the mouth of the goat along the esophagus. The sampling head is a hard plastic tube with 3 cm in diameter and 90 cm in length. The vacuum pressure was set at 65 kPa. To minimize saliva contamination, approximately 30 ml of rumen fluid was discarded before actual sample collection. Samples were immediately filtered through four-layer gauze. Rumen pH was measured immediately using a portable pH meter (Model PHB-4, Shanghai Leica Scientific Instrument Co., Ltd., Shanghai, China). Rumen fluid samples were placed in a 50 ml centrifuge tube and centrifuged at 9,500 rpm for 3 min. The V4 regions of bacterial 16S rRNA genes were amplified. The bacterial sequences were amplified using primers 338F ACTCCTACGGGAGGCAGCAG and 806 R GGACTACHVGGGTWTCTAAT. The bacterial amplification mixture consisted of 0.8 μl (5 μM) of each primer, 10 ng template DNA, 4 μl 5×Fast Path buffer, 2 μl 2.5 mM dNTPs, 0.4 μl FastPfu polymerase, 0.2 μl L bovine serum albumin (BSA), and added ddH₂O to 20 μl. Amplification was performed with initial denaturation at 95 °C for 3 min; 30 cycles of denaturation at 95 °C for 30 s, annealing at 50 °C for 30 s, and elongation at 72 °C for 45 s. PCR products were excised from 2% agarose gels and purified with a QIAquick Gel Extraction Kit (Qiagen, Venlo, The Netherlands). The remaining DNA was sent to Shanghai Majorbio Biological Technology Co. Ltd for sequencing using an Illumina MiSeq PE250 (Illumina, San Diego, CA, USA).
TABLE 1 | The effect of supplementation of bovine lactoferrin (BLFc) at the rate of 100 mg/kg/day (LF-1) or 200 mg/kg/day (LF-2) on the serum lactoferrin (LF) levels of dairy goats over time.

| Item                  | Time point (day) | Control          | LF-1              | LF-2              | SEM     | p-value   | Treatment | Time | Treatment*Time |
|-----------------------|------------------|------------------|-------------------|-------------------|---------|-----------|-----------|------|----------------|
| LF in the serum (µg/mL) |                  |                  |                   |                   |         |           |           |      |                |
|                       | 0                | 158.68<sup>B</sup> | 160.24<sup>B</sup> | 192.19<sup>C</sup> | 8.67    | 0.211     |           |      |                |
|                       | 14               | 153.74<sup>BC</sup> | 195.65<sup>B</sup> | 259.59<sup>IA</sup> | 11.56   | <0.01     | 0.029     | <0.01|                |
|                       | 28               | 151.64<sup>BC</sup> | 246.97<sup>AA</sup> | 252.46<sup>IA</sup> | 12.29   | <0.01     | <0.01     | <0.01|                |
|                       | 42               | 198.00<sup>AC</sup> | 252.77<sup>AB</sup> | 309.98<sup>AA</sup> | 13.62   | 0.01      | <0.01     | <0.01|                |

abc Treatment means with different letter differ (p < 0.05) in the same line; ABC Treatment means with different letter differ (p < 0.05) in the same column.

TABLE 2 | The effect of supplementation of BLFc at the rate of 100 mg/kg/day (LF-1) or 200 mg/kg/day (LF-2) on IgA, Fe, total antioxidant content (T-AOC), and Malondialdehyde (MDA) in the serum of dairy goats.

| Item                  | Time point (day) | Control (n = 7) | LF-1 (n = 7) | LF-2 (n = 7) | SEM     | p-value   | Treatment | Time | Treatment*Time |
|-----------------------|------------------|-----------------|--------------|--------------|---------|-----------|-----------|------|----------------|
| IgA in the serum (µg/mL) |                  |                 |              |              |         |           |           |      |                |
|                       | 0                | 428.01<sup>BBC</sup> | 438.47<sup>AB</sup> | 487.15<sup>IA</sup> | 9.77    | 0.021     |           |      |                |
|                       | 14               | 408.96<sup>BC</sup> | 504.55<sup>AA</sup> | 556.72<sup>AA</sup> | 17.25   | <0.01     | 0.057     | <0.01|                |
|                       | 28               | 488.52<sup>B</sup> | 526.23<sup>ABA</sup> | 573.25<sup>AA</sup> | 14.31   | <0.01     | <0.01     | <0.01|                |
|                       | 42               | 468.31<sup>AB</sup> | 532.35<sup>AA</sup> | 574.15<sup>AA</sup> | 15.17   | <0.01     | <0.01     | <0.01|                |
| Fe (µmol/L)            |                  |                 |              |              |         |           |           |      |                |
|                       | 0                | 69.73<sup>B</sup> | 83.02<sup>B</sup> | 65.66<sup>B</sup> | 9.50    | 0.749     |           |      |                |
|                       | 14               | 124.53<sup>A</sup> | 111.96<sup>AB</sup> | 109.76<sup>A</sup> | 5.55    | 0.524     | <0.01     | 0.018|                |
|                       | 28               | 88.59<sup>AB</sup> | 136.17<sup>AA</sup> | 145.36<sup>AA</sup> | 10.35   | 0.032     | <0.01     | <0.01|                |
|                       | 42               | 101.84<sup>AB</sup> | 123.42<sup>A</sup> | 112.68<sup>A</sup> | 8.88    | 0.645     | <0.01     | 0.092|                |
| T-AOC (U/mL)           |                  |                 |              |              |         |           |           |      |                |
|                       | 0                | 1.04<sup>A</sup> | 0.98<sup>B</sup> | 1.20         | 0.12    | 0.730     |           |      |                |
|                       | 14               | 1.55<sup>B</sup> | 1.47<sup>B</sup> | 1.30         | 0.08    | 0.479     | 0.096     | <0.01|                |
|                       | 28               | 1.09<sup>B</sup> | 1.67<sup>AA</sup> | 1.67<sup>A</sup> | 0.10    | 0.014     | 0.113     | <0.01|                |
|                       | 42               | 1.34<sup>B</sup> | 1.69<sup>A</sup> | 1.57         | 0.08    | 0.630     | 0.073     | <0.01|                |
| MDA (nmol/mL)          |                  |                 |              |              |         |           |           |      |                |
|                       | 0                | 9.08<sup>BC</sup> | 12.14<sup>AB</sup> | 8.81<sup>AB</sup> | 0.79    | 0.159     |           |      |                |
|                       | 14               | 6.12<sup>B</sup> | 6.84<sup>B</sup> | 5.88<sup>B</sup> | 0.48    | 0.728     | 0.045     | <0.01|                |
|                       | 28               | 10.20<sup>AB</sup> | 4.93<sup>B</sup> | 10.12<sup>AB</sup> | 0.91    | 0.018     | 0.203     | 0.016|                |
|                       | 42               | 14.00<sup>A</sup> | 10.44<sup>A</sup> | 10.93<sup>A</sup> | 0.95    | 0.257     | 0.159     | 0.130|                |

abc Treatment means with different letter differ (p < 0.05) in the same line; ABC Treatment means with different letter differ (p < 0.05) in the same column.

Statistical Analysis
The data were analyzed using SPSS 19.0 statistical software (version 19, SPSS Inc, Chicago, IL, USA). Repeated measure analysis was used with all data presented as least squares means and pooled SEM. Significant differences were declared at p < 0.05. Spearman’s correlation test was used to examine relationships between serum LF and milk LF concentrations. Meanwhile, the general linear model (GLM) was used to conduct multi-variance ANOVA for BLFc levels and feeding time. The differences between groups were discussed when there was significant interaction between the treatment factors. Rumen microbial diversity sequence reads were divided and aligned into operational taxonomic units (OTUs) with 97% sequence similarity. The highest abundance sequences were compared with template regions in the Greengenes database (Vsession https://drive5.com/uparse/ 7.0), and used to acquire taxonomic information for each OTU and species composition. To obtain the species classification information corresponding to each OTU, the comparison database of 16S rRNA of bacteria and archaea was used (Silva, Release138 https://www.arb-silva.de). R software was used to analyze the microflora population structures (1:4).

RESULTS
LF Levels
All goats remained healthy throughout the entire experiment with no adverse health effects from the supplementation of BLFc. Dietary supplementation of 100 or 200 mg/kg/day of BLFc did not affect daily feed intake (Supplementary Table 2, p > 0.05). At the beginning of the experiment, serum LF concentrations were not different (p > 0.05) among the three groups (Table 1). With the time elongation, BLFc supplementation increased LF concentration in the serum, with higher concentrations in LF-1 group on day 28 and LF-2 group on day 42 (Table 1, p < 0.05). Multivariate analysis of variance between the treatment times suggested that serum LF had significant differences among the three groups at the same treatment time. Serum
LF concentrations of all 21 dairy goats trended higher in the experimental period, and both LF-1 group and LF-2 group affected the serum LF. We also observed the interaction between BLFc supplementation and time on serum LF (Table 1, \( p < 0.05 \)). The results indicated that in LF-1 group and LF-2 group on day 42, there were 57.50 and 61.28% higher concentrations of LF than day 0 of the experiment, respectively. Correlation analysis indicated that serum LF was positively correlated with milk LF in LF-1 group and LF-2 group (Supplementary Figures 1, 2, \( p < 0.01 \)).

**Physiological Functions**

Multivariate ANOVA between the treatment time and BLFc supplementation indicated that serum IgA was different among the three groups at the same treatment time. Although serum IgA of all 21 dairy goats trended higher in the experimental period, supplementation of BLFc increased serum IgA significantly (Table 2, \( p < 0.05 \)). Serum IgA in the LF-1 group was higher than the control group (Table 2, \( p < 0.05 \)). Within the same treatment time, differences in serum Fe were observed among three groups (Table 2, \( p < 0.05 \)). Compared to the control group, higher serum Fe and T-AOC were observed in the LF-1 group and the LF-2 group on day 28 (Table 2, \( p < 0.05 \)). Meanwhile, serum MDA in the LF-1 group was lower than that in the control group and the LF-2 group on day 28 (Table 2, \( p < 0.05 \)). Multivariate analysis of treatment time and BLFc supplementation indicated that serum MDA was different among the three groups on day 28 (Table 2, \( p < 0.05 \)). The LF-1 group on day 28 had 20.02, 64.02, and 70.41% higher concentrations of IgA, Fe, and T-AOC than at the onset of the treatment, respectively. Serum MDA at the same time was 59.39% lower than at the onset of treatment in the LF-1 group.

**Ruminal Microorganisms**

Rumen pH in the LF-2 group was lower than that in the LF-1 group and the control group (Figure 1A, \( p < 0.05 \)). There was no difference in pH value between the LF-1 group and the control group (Figure 1A, \( p > 0.05 \)). The sequencing data, based on the principle that the similarity is >97%, were divided into OTUs. With the removal of low-quality reads from sequencing data, we obtained 326,508 total sequences for bacteria, with an average of 100,825 sequences per sample. There were 1,498, 1,455, and 1,417 OTUs in the control group, LF-1 group, and LF-2 group, respectively. The three groups had a total of 1,228 OTUs (Figure 1B).

Goat rumen was found to be dominated by two bacterial phyla, Bacteroidetes and Firmicutes, while other phyla, such as Proteobacteria, Tenericutes, and Actinobacteria were less in numbers (Figure 1C). At the phylum level, Bacteroidetes were significantly decreased and Firmicutes were significantly increased in LF-2 group compared with the control group and the LF-1 group (Figures 1C, E). The three most abundant phyla in LF-1 group and the control group were Bacteroidetes, Firmicutes, and Tenericutes. However, Firmicutes in LF-2 group was the most abundant (Figures 1C, E). At the genus level, the average relative abundance of Prevotella 1 gut in LF-1 group was higher \( (p < 0.05) \) than that in LF-2 group (Figures 1D, F). The relative abundance of succiniclasticum in LF-2 group was higher \( (p < 0.05) \) than that in the LF-1 group and the control group (Figures 1D, F).

**Performance of Lactating Goats**

There was no difference in milk yield among the three groups (Table 3, \( p > 0.05 \)), with a trend of higher milk yield in BLFc-treated group on day 42. The results showed that the control group had 17.59% lower milk production at the end of the 6-week treatment (Table 3, \( p < 0.05 \)). Neither the LF-1 group nor the LF-2 group showed any effect on the milk yield greatly (Table 3, \( p > 0.05 \)). However, the supplementation of BLFc affected the milk composition. Milk fat in LF-2 group on day 28 was lower than that in the control group and LF-1 group (Table 4, \( p < 0.05 \)).

**Bioactive Substances in Milk**

Milk SCC was reduced in the LF-1 and LF-2 groups. The SCC in the LF-1 group and the LF-2 group was lower compared with the control group on day 42 (Table 5, \( p < 0.05 \)). Milk IgA concentrations in goats received BLFc supplementation were higher than the control group on day 42 (Table 6, \( p < 0.05 \)). Milk IgA in the LF-2 group was the highest among the three groups (Table 6, \( p < 0.05 \)). Milk LF concentrations in goats that received BLFc supplementation were higher than that in the control group, and in the LF-2 group being the highest (Table 6, \( p < 0.05 \)). Moreover, the results showed that there was a trend of higher IgA and LF in milk in the LF-1 and LF-2 groups. The LF-1 and LF-2 groups on day 42 had 45.20 and 29.55% higher concentrations of IgA in the milk than at the beginning of the treatment, respectively. The LF-1 and LF-2 groups on day 42 had 60.66 and 39.45% higher concentrations of LF in the milk than at the beginning of the treatment, respectively. There were the interactions between BLFc-treated concentration and BLFc-treated time on both IgA level and LF level in the milk of dairy goats (Table 6, \( p < 0.05 \)).

**DISCUSSION**

This study suggested that BLFc decreased the rumen pH value and altered the composition of rumen microbiota. Higher dose of BLFc appeared to increase the ratio of Firmicutes phylum to Bacteroidetes phylum and decreased the abundance of Prevotella genus. The phylum of Bacteroidetes and Firmicutes were the most abundant phylum in rumen of the ruminant animal, and Prevotella is the most abundant genus. The increased ratio of Firmicutes phylum to Bacteroidetes phylum (F/B) will result in an increase in energy availability from the feed. The abundance of Firmicutes is associated with the degradation of fermentable carbohydrates (15). It is known that Bacteroidetes phylum is predominantly Gram-negative bacteria and sensitive to the change of environmental pH value (16). We also observed that Butyrivibrio genus and Succiniclasticum genus were depleted in BLFc-treated goats. It implied that BLFc altered the type of rumen fermentation. Several studies showed that the diversity and structure of ruminal microbiota affected the immune system (17–19). Antimicrobial peptides promote the abundance of Firmicutes and Tenericutes and increase LF synthesis in the
The effect of supplementation of BLFc at the rate of 100 mg/kg/day (LF-1) or 200 mg/kg/day (LF-2) on (A) rumen pH, (B) number of operational taxonomic unit (OTU), (C) rumen microbial diversity at the phylum level, (D) rumen microbial diversity at the genus level in dairy goats, (E) effects of BLFc on the relative abundance of rumen microbiota at phylum levels in goats, and (F) effects of BLFc on the relative abundance of rumen microbiota at genus levels in goats. In (A), (E), and (F), treatment means with different letters differ ($p < 0.05$).
The decrease of \textit{Butyrivibrio} genus reduced the formation of butyric acids and finally affected the milk fat (23), the last result of which has been observed in this study. In addition, some research certified that the formation of propionic acid in goat rumen is increased with the decrease of butyric acids (24–26). The high levels of propionic acid greatly improve the digestion and absorption of concentrated feed and furthermore increase the lactating performance of dairy goat, so we found that the milk yield in the dairy goat is improved in this experiment. The results demonstrated that BLFc supplementation in diet possibly alters the composition of rumen microbiota, with the strong alterations observed in the LF-2 group.

It has been reported that the levels of IgA and LF were related to SCC in the milk, and could be useful indicators for the detection of subclinical mastitis (27). We speculated that BLFc promoted lymphocyte differentiation, reduced the number of neutrophils, and enhanced the innate and adaptive immune (28). Although SCC in goats with BLFc supplementation was statistically different compared with the goats in the control group, the average SCC of goats with BLFc supplementation on day 42 was greatly lower than that in the control group ($p < 0.05$). The SCC represents the total cell count in goat milk, mostly are immune cells, such as macrophages, neutrophils, and lymphocytes (29). IgA could be effective to combat bacteria, such as \textit{Staphylococcus aureus} and \textit{Streptococcus agalactiae} infecting mammary epithelial cells (30). We observed that BLFc supplementation to the goats could increase the levels of LF in serum and milk and IgA in milk. Although the levels of LF in serum and milk were affected by the time and treatment interactions, the effect of BLFc supplementation over time was apparent. This suggests that LF supplementation at both levels could effectively increase the levels of LF in serum and milk, and the absorption and utilization of added BLFc by dairy goats was effective. These studies suggested that BLFc had a positive role on immune regulation. The LF is capable of passing through the blood/milk barrier (31–33) and plays a role in protecting the mammary gland from bacterial invasion.

Furthermore, the LF is a non-heme-iron glycoprotein that can promote the absorption and storage of iron (34). Iron, as an important constituent of hemoglobin, can improve the antioxidant capacity in serum and enhance cellular immunity. In the present study, there were elevated serum iron and T-AOC, and lower MDA level in goats with BLFc supplementation compared with the control group on day 28, which implied that

\begin{table}
\centering
\caption{The effect of supplementation of BLFc at the rate of 100 mg/kg/day (LF-1) or 200 mg/kg/day (LF-2) on milk production throughout the experiment.}
\begin{tabular}{lcccccc}
\hline
Time & Control & LF-1 & LF-2 & SEM & $p$-value \\
\hline
Average milk production per day of the first week & 2.16$^A$ & 2.19$^A$ & 1.95 & 0.06 & 0.488 \\
Average milk production per day of the second week & 1.91$^B$ & 1.95$^B$ & 1.86 & 0.05 & 0.769 \\
Average milk production per day of the third week & 2.06$^A$ & 2.06$^A$ & 1.87 & 0.07 & 0.484 \\
Average milk production per day of the fourth week & 1.93$^B$ & 2.07$^A$ & 1.94 & 0.08 & 0.696 \\
Average milk production per day of the fifth week & 1.79$^B$ & 2.01$^A$ & 1.87 & 0.08 & 0.474 \\
Average milk production per day of the sixth week & 1.78$^B$ & 2.06$^A$ & 1.94 & 0.08 & 0.319 \\
\hline
\end{tabular}
\end{table}

\begin{table}
\centering
\caption{The effects of supplementation of BLFc at the rate of 100 mg/kg/day (LF-1) or 200 mg/kg/day (LF-2) on the milk composition in dairy goats.}
\begin{tabular}{lcccccc}
\hline
Time point (day) & Item & Control & LF-1 & LF-2 & SEM & $p$-value \\
\hline
0 d & Fat (%) & 3.73 ± 1.47 & 4.37 ± 1.96 & 3.94 ± 1.54 & 0.36 & 0.78 \\
 & Protein (%) & 3.45 ± 0.54 & 3.28 ± 0.15 & 3.08 ± 0.27 & 0.08 & 0.20 \\
 & Lactose (%) & 5.02 ± 0.26 & 5.05 ± 0.21 & 4.92 ± 0.26 & 0.53 & 0.56 \\
14 d & Fat (%) & 4.26 ± 0.63 & 4.30 ± 0.76 & 3.65 ± 0.61 & 0.15 & 0.16 \\
 & Protein (%) & 3.41 ± 0.36 & 3.24 ± 0.23 & 3.17 ± 0.21 & 0.06 & 0.26 \\
 & Lactose (%) & 4.95 ± 0.27 & 4.99 ± 0.22 & 4.94 ± 0.27 & 0.53 & 0.94 \\
28 d & Fat (%) & 4.21 ± 0.86$^a$ & 4.18 ± 0.60$^a$ & 3.30 ± 0.50$^b$ & 0.17 & 0.03 \\
 & Protein (%) & 3.43 ± 0.46 & 3.22 ± 0.18 & 3.08 ± 0.20 & 0.07 & 0.12 \\
 & Lactose (%) & 4.77 ± 0.16 & 4.76 ± 0.15 & 4.78 ± 0.14 & 0.03 & 0.97 \\
42 d & Fat (%) & 4.19 ± 0.92 & 4.17 ± 0.71 & 3.46 ± 0.59 & 0.17 & 0.15 \\
 & Protein (%) & 3.44 ± 0.71 & 3.10 ± 0.22 & 2.95 ± 0.24 & 0.10 & 0.14 \\
 & Lactose (%) & 4.66 ± 0.28 & 4.85 ± 0.11 & 4.76 ± 0.28 & 0.05 & 0.35 \\
\hline
\end{tabular}
\end{table}

$^ABC$ Treatment means with different letter differ ($p < 0.05$) in the same column.

$^a$ Treatment means with different letter differ ($p < 0.05$) in the same line.
TABLE 5 | Effects of supplementation of BLFc at 100 mg/kg/day (LF-1) or 200 mg/kg/day (LF-2) on milk somatic cell counts (SCCs) (×1,000/ml) in dairy goats.

| Item                        | Time point (day) | Control   | LF-1       | LF-2       | SEM      | p-value |
|-----------------------------|------------------|-----------|------------|------------|----------|---------|
| Milk somatic cell counts    | 0                | 304.14    | 272.75     | 270.38     | 44.69    | 0.950   |
|                             | 14               | 225.50    | 151.13     | 163.60     | 51.09    | 0.832   |
|                             | 28               | 483.80    | 366.29     | 242.25     | 73.17    | 0.447   |
|                             | 42               | 407.38a   | 169.63b    | 63.83b     | 53.34    | 0.019   |

Note: Treatment means with different letter differ (p < 0.05) in the same line.

TABLE 6 | Effects of supplementation of BLFc at 100 mg/kg/day (LF-1) or 200 mg/kg/day (LF-2) on milk IgA and lactoferrin in dairy goats.

| Item                        | Time point (day) | Control   | LF-1       | LF-2       | SEM      | p-value |
|-----------------------------|------------------|-----------|------------|------------|----------|---------|
| IgA in milk (µg/mL)         | 0                | 227.20AB  | 220.93ABC  | 238.29bc  | 8.14     | 0.70    | –       | –       |
|                             | 14               | 205.43ab  | 257.84ca   | 288.17ab  | 11.06    | <0.01  | 0.122  | –       |
|                             | 28               | 236.13ab  | 294.60ab   | 322.23ab  | 11.17    | <0.01  | <0.01  | <0.01  |
|                             | 42               | 250.35ab  | 320.79ab   | 308.70ab  | 10.49    | <0.01  | <0.01  | <0.01  |
| LF in milk (µg/mL)          | 0                | 273.48ab  | 283.82ab   | 343.12ab  | 13.16    | 0.058  | –       | –       |
|                             | 14               | 290.34ab  | 356.17ab   | 404.90ab  | 14.92    | <0.01  | 0.029  | <0.01  |
|                             | 28               | 365.51ab  | 450.63ab   | 439.30ab  | 12.92    | <0.01  | <0.01  | <0.01  |
|                             | 42               | 382.96ab  | 458.99ab   | 478.47ab  | 12.73    | <0.01  | <0.01  | <0.01  |

Note: Treatment means with different letter differ (p < 0.05) in the same line; ABC Treatment means with different letter differ (p < 0.05) in the same column.

BLFc possibly promoted the absorption of iron and oxidizing ability. These findings demonstrated that BLFc as an antioxidant will scavenge hydroxyl radicals and reduce the damage of active oxygen to the body. It was similar to the reported research that BLFc has many protective effects, such as reducing the levels of MDA, catalase, and glutathione in the serum and enhancing the antioxidant capacity in lambs (35).

CONCLUSION
The study provided important evidence that 100 mg/kg/day BLFc supplementation to the diet of lactating dairy goats is capable of decreasing oxidative stress and inhibiting inflammation.

DATA AVAILABILITY STATEMENT
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: NCBI BioProject, PRJNA742184.

ETHICS STATEMENT
The animal study was reviewed and approved by the experiment was carried out with the approval of the Animal Use and Care Committee of Northwest A&F University in China (No.IASCAAS-PG-39). Written informed consent was obtained from the owners for the participation of their animals in this study.

FINANCIAL STATEMENT
This research was jointly supported by the Innovation Support Plan of Shaanxi Province (No.2021TD-31), the National Natural Science Foundation of China (31672398), and the Xi’an Science and Technology Project (20NYYF0030).

ACKNOWLEDGMENTS
The authors gratefully acknowledge the staff of Saanen Dairy Goat Farm of Northwest A&F University for their help in the care of the animals and in all the phases of the experiment.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2021.722303/full#supplementary-material
REFERENCES

1. Wang B, Timilsena YP, Blanche E, Adhikari B. Lactoferrin: structure, function, mechanism of action and potential applications. Curr Food Sci Technol. (2019) 15:807–17. doi:10.2174/187150281966619031515183
2. Hao L, Shan Q, Wei J, Ma F, Sun P. Lactoferrin: major physiological functions and applications. Curr Protein Pept Sci. (2018) 19:139. doi:10.2174/1389203719666180514150921
3. Moreno-Expósito I, Illescas-Montes R, Melguizo-Rodríguez L, Ruiz C, Ramos-Torrecillas J, de Luna-Bertos E. Multifunctional capacity and therapeutic potential of lactoferrin. Life Sci. (2018) 195:61–4. doi:10.1016/j.lfs.2018.01.002
4. Karav S, German J, Rouquié C, Le Parc A, Barile D. Studying lactoferrin functions and applications. Curr Protein Pept Sci. (2017) 18:870. doi:10.2174/13892037196661706040870
5. Wang Q, Cai R, Huang A, Wang X, Qu W, Shi L, et al. Comparison of oopharyngeal microbiota in healthy piglets and piglets with respiratory disease. Front Microbiol. (2018) 9:3218. doi:10.3389/fmicb.2018.03218
6. Xiao H, Tan BE, Wu MM, Yin YL, Li TJ, Yuan DX, et al. Effects of composite antimicrobial peptides in weaning piglets challenged with deoxyribonucleic acid (DNA) and RNA. Animal Health Research Reviews. (2017) 18:870. doi:10.3390/jmbs.18065633
7. Yan L, Zhang B, Shen Z. Dietary modulation of the expression of genes involved in short-chain fatty acid absorption in the rumen epithelium is related to short-chain fatty acid concentration and pH in the ruminant. J Dairy Sci. (2014) 97:4750–6. doi:10.3168/jds.2013-6427
8. Tang Z, Yin Y, Zhang Y, Huang R, Sun Z, Li T, et al. Effects of dietary supplementation with an expressed fusion peptide bovine lactoferrin-lactoferricin on performance, immune function and intestinal mucosal morphology in pigs weaned at age 21 d. Br J Nutr. (2009) 101:998–1005. doi:10.1017/S000711450900027X
9. Yen T, Sibbald S, Zhao Q, et al. Alteration in immune responsiveness during the peripartum period and its ramification on dairy cow and calf health. J Dairy Sci. (2011) 94:3960–72. doi:10.3168/jds.2010-4041
10. Isobe N, Matsukawa S, Kubo K, Ueno K, Sugino T, Nii T, et al. Effects of oral administration of colostrum whey in peripartum goat on antimicrobial peptides in postpartum milk. Anim Sci J. (2020) 91:e13365. doi:10.1111/asj.13365
11. Shi J, Zhang P, Xu MM, Fang Z, Lin Y, Che L, et al. Effects of composite antimicrobial peptide on growth performance and health in weaned piglets. Anim Sci J. (2018) 89:397–403. doi:10.1111/asj.12933
12. Zou C, Gu Q, Zhou X, Xia Z, Muhammad WI, Tang Q, et al. Ruminal microbiota composition associated with ruminal fermentation parameters and milk yield in lactating buffalo in Guangxi. China-a preliminary study. Anim Sci J. (2019) 103:1574–79. doi:10.1111/asj.13154
13. Serment A, Giger-Reverdin S, Schmidely P, Dhumoze O, Broudecou LP, Sauvant D. In vitro formation of total mixed diets differing in concentrate proportion: relative effects of inocula and substrates. J Sci Food Agric. (2016) 96:160–8. doi:10.1002/jsfa.7076
14. Serment A, Schmidely P, Giger-Reverdin S, Chapoutot P, Sauvant D. Effects of the percentage of concentrate on rumen fermentation, nutrient digestibility, plasma metabolites, and milk composition in mid-lactation goats. J Dairy Sci. (2011) 94:6960–72. doi:10.3168/jds.2010–4041
15. Molina-Alcaide E, Pascual MR, Cantalapiedra-Hijar G, Morales-García EJ, Martin-García AL. Effects of concentrate replacement by feed blocks on ruminal fermentation and microbial growth in goats and single-flow continuous-culture fermenters. J Anim Sci. (2009) 87:1321–33. doi:10.2527/jas.2008–1263
16. Lindmark-Månsson H, Bränning C, Aldén G, Paulsson M. Relationship between somatic cell count, individual leukocyte populations and milk components in bovine udder quarter milk. Int Dairy J. (2006) 16:717–27. doi:10.1016/j.idairyj.2005.07.003
17. Khuyen TD, Mandili S, Corret V, Douxfils J, Betouille S, Bossier P, et al. Physiological and immune response of juvenile rainbow trout to dietary bovine lactoferrin. Fish Shellfish Immunol. (2017) 71:359–71. doi:10.1016/j.fsi.2017.10.027
18. Lipkens Z, Piepers S, Verbeke J, De Vliegher S. Infection dynamics across the dry period using Dairy Herd Improvement somatic cell count data and its effect on cow performance in the subsequent lactation. J Dairy Sci. (2019) 102:640–51. doi:10.3168/jds.2018–15130
19. Mallard BA, Dekkers JC, Ireland MJ, Leslie KE, Sharif S, Vankampen CL, et al. Alteration in immune responsiveness during the peripartum period and its ramifications on dairy cow and calf health. J Dairy Sci. (1998) 81:585–95. doi:10.3168/jds.2002-032098(98)5612-7
20. Soboleva SE, Tuzikov VF, Tuzikova NA, Buneva VN, Nevinskii GA. DNA and oligosaccharides stimulate oligomerization of human milk lactoferrin. Mol Biol. (2009) 43:157–65. doi:10.1134/S0026893309010191
21. Babina SE, Semenov DV, Buneva VN, Nevinskii GA. Human milk lactoferrin hydrolyzes nucleoside-5′-triphosphates. Mol Biol. (2005) 39:513–20. doi:10.1016/S0026-8933(05)0061-5
22. Hayashida K, Takeuchi T, Ozaki T, Shimizu H, Ando K, Miyamoto A, et al. Bovine lactoferrin has a nitric oxide-dependent hypotensive effect in rats. Am J Physiol Regul Integr Comp Physiol. (2004) 286:R359–65. doi:10.1152/ajpregu.002012.42003
23. Liu H, Wu H, Zhu N, Xu Z, Wang Y, Qu Y, et al. Lactoferrin protects against iron dysregulation, oxidative stress, and apoptosis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson’s disease in mice. J Neurochem. (2020) 152:397–415. doi:10.1111/jnc.14857
24. El-Ashker M, Risha E, Abdelhamid F, Ateya A. Potential immune modulating properties and antioxidant activity of supplementing flow continuous-culture fermenters.
commercially available lactoferrin and/or Lactobacillus sp. in healthy Ossimi lambs. Pol J Vet Sci. (2018) 21:705–13. doi: 10.24425/124309

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Shao, Zhang, Zhang, Tian, Weng, Huang, Lu and Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.